Investing.com - Viking Therapeutics Inc (NASDAQ: VKTX) reported first quarter EPS of $-0.250, $0.01 worse than the analyst estimate of $-0.240. Revenue for the quarter came in at ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Viking Therapeutics, Inc (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today ...

The chart below shows the one year performance of VKTX shares: Looking at the chart above, VKTX's low point in its 52 week range is $20.28 per share, with $99.41 as the 52 week high point — that ...

The stock also underperformed the broader Medical sector and the S&P 500 during this timeframe, as shown in the chart below. VKTX’s shares are currently trading below the 50 and 200-day moving ...

Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s 5.3% decline. The stock also underperformed the broader Medical sector and ...